Literature DB >> 25965568

Defining the molecular landscape of ependymomas.

Tenley C Archer1, Scott L Pomeroy2.   

Abstract

Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2015        PMID： 25965568     DOI： 10.1016/j.ccell.2015.04.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

Review 1.  Supratentorial pediatric cortical ependymomas: a comprehensive retrospective study.

Authors:  Qiguang Wang; Jian Cheng; Si Zhang; Qiang Li; Xuhui Hui; Yan Ju
Journal:  Neurosurg Rev       Date:  2020-06-30       Impact factor: 3.042

Review 2.  Medulloblastoma: Molecular Classification-Based Personal Therapeutics.

Authors:  Tenley C Archer; Elizabeth L Mahoney; Scott L Pomeroy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

3.  Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.

Authors:  Chunjui Chen; Lingchao Chen; Yu Yao; Zhiyong Qin; Hong Chen
Journal:  J Neurooncol       Date:  2015-11-28       Impact factor: 4.130

4.  Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.

Authors:  Maura Massimino; Francesco Barretta; Piergiorgio Modena; Hendrik Witt; Simone Minasi; Stefan M Pfister; Kristian W Pajtler; Manila Antonelli; Lorenza Gandola; Maria Luisa Garrè; Daniele Bertin; Angela Mastronuzzi; Maurizio Mascarin; Lucia Quaglietta; Elisabetta Viscardi; Iacopo Sardi; Antonio Ruggiero; Bianca Pollo; Annamaria Buccoliero; Luna Boschetti; Elisabetta Schiavello; Luisa Chiapparini; Alessandra Erbetta; Isabella Morra; Marco Gessi; Vittoria Donofrio; Carlo Patriarca; Felice Giangaspero; Pascal Johann; Francesca Romana Buttarelli
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

5.  Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient.

Authors:  Christopher A Miller; Sonika Dahiya; Tiandao Li; Robert S Fulton; Matthew D Smyth; Gavin P Dunn; Joshua B Rubin; Elaine R Mardis
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

6.  Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread.

Authors:  Kristen A Batich; Richard F Riedel; John P Kirkpatrick; Betty C Tong; William C Eward; Char Loo Tan; Patricia D Pittman; Roger E McLendon; Katherine B Peters
Journal:  Front Oncol       Date:  2019-11-28       Impact factor: 6.244

Review 7.  Citation analysis of the most influential ependymoma research articles illustrates improved knowledge of the molecular biology of ependymoma.

Authors:  Nolan J Brown; Bayard Wilson; Brian V Lien; Alexander Himstead; Ali R Tafreshi; Shane Shahrestani; Jack Birkenbeuel; Katelynn Tran; David Horton; Anushka Paladugu; Lydia R Kirillova; Chen Yi Yang; Seth C Ransom; Ronald Sahyouni; Isaac Yang
Journal:  Neurosurg Rev       Date:  2021-10-06       Impact factor: 3.042

Review 8.  Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Liping Liu; Yunqian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.